European Patent Office

T 1708/18 (PCSK9 variants/BRISTOL-MYERS SQUIBB) du 14.02.2022

Identifiant européen de la jurisprudence
ECLI:EP:BA:2022:T170818.20220214
Date de la décision
14 février 2022
Numéro de l'affaire
T 1708/18
Requête en révision de
-
Numéro de la demande
07873840.8
Classe de la CIB
A61K 38/00C12N 9/64
Langue de la procédure
Anglais
Distribution
Non distribuées (D)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
Résumé de EPC2000 Art 117
Titre de la demande
Polynucleotides encoding novel PCSK9 variants
Nom du demandeur
Bristol-Myers Squibb Company
Nom de l'opposant
Regeneron Pharmaceuticals, Inc.
Sanofi
Pfizer Inc.
Chambre
3.3.04
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 54
Mots-clés
Novelty - (no)
Exergue
1. The issue of which standard of disclosure applies when assessing the legal question of novelty and the issue of which standard of proof applies when assessing evidence and factual questions are distinct and unrelated. The fact that the standard of disclosure required for a finding of lack of novelty (or for allowing an amendment to the application under Article 123(2) EPC) is the standard of a direct and unambiguous disclosure is immaterial for the question of what standard of proof applies when considering evidence and factual issues in the context of novelty (or inventive step) (see point 16).
2. The standard of proof generally applied at the EPO for deciding on an issue of fact is the balance of probabilities. According to this standard, the EPO must base its decisions on statements of fact which, based on the available evidence, are more likely than not to be true. This standard also applies when examining factual issues in the context of novelty (see point 14).
Affaires citantes
T 0358/22

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.